-
2023-504989-37-00
5
Metastatic Squamous Non-small Cell Lung Cancer
-
2023-506014-47-00
9
Resected (R0 or R1) pancreatic ductal adenocarcinoma
-
2023-508476-11-00
1
Adenoid cystic carcinoma (ACC)
-
2023-507485-10-00
9
2026-04-21
advanced breast cancer
-
2023-504445-31-00
4
2024-09-19
Carcinoma, Head and Neck
-
2023-506227-29-00
3
2024-08-30
locally advanced or metastatic solid tumors
-
2023-503523-25-00
4
2024-02-29
Non-small cell lung cancer
-
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
2024-511818-21-00
5
2026-03-06
Acute law back pain
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
-
2023-506539-14-00
3
2025-05-27
Oncology
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-510893-25-00
5
2025-04-29
Brain metastases of cancer > brain radionecrosis
-
2023-508507-20-00
5
2025-04-03
Locally advanced or metastatic conventional chondrosarcoma with an IDH
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2023-507482-26-00
5
2024-10-04
Castrate-resistant prostate cancer with oligometastases on functional
-
2023-503316-33-00
5
2024-09-26
patients with a positive status for molecular residual disease (MRD) [
-
2024-515118-42-00
11
2024-09-10
Colorectal cancer
-
2022-502408-57-00
5
2024-09-04
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
-
2023-505298-34-00
4
2024-07-18
Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanc
-
2023-508100-38-00
5
2024-06-24
Advanced Biliary Cancer (ABC)